{"entity":{"id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","aka":[],"tldr":"A phase 1/2 trial of Bevacizumab in cervical cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer is a phase 1/2 interventional study registered as NCT07080216 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 120 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-08. Interventions recorded: ZG005, Gecacitinib, Bevacizumab. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07080216","url":"https://clinicaltrials.gov/study/NCT07080216"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["bevacizumab"],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07080216","phase":"1/2","setting":"A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","participation":[{"nct":"NCT07080216","source":"https://clinicaltrials.gov/study/NCT07080216","fetchedAt":"2026-10-07T16:55:25.997Z","studySha256":"1d7fb4ffbd3d27cf7e03d4e65aaf7d43d1cd681ab704c955b4654f33bab64974","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-05","leadSponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":120,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-09-23","startedType":"actual","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07080216/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}